new-kit-box

Measure Canine Neonatal Fc Receptor Binding to IgG Molecules

  • Powerful alternative to traditional ELISAs
  • High sensitivity and broad dynamic range: 3–4 logs
  • Solution-based: no immobilization artifacts
  • Flexible formats: 96- or 384-well plates

Lumit® Canine FcRn Binding Immunoassay

  Catalog No. Product Name   Size Price Qty  
CS3019A02 Early Access Lumit® Canine FcRn Binding Immunoassay View Specifications 1 each     Please Enquire

Early Access = This product is available under our Early Access program - Learn More

Catalog (FT) = This product is available under our Catalog (FT) program - Learn More

Overview
Protocols
Specifications
Resources
Related Products

Unleash A Faster, Simpler Canine Immunoassay

Very little is known about the functional characteristics of canine IgG subclasses, including to what degree the various classes bind Fc receptors, engage the immune system or their half-life in serum. Understanding the binding affinities of the canine IgG subclasses to immune effector proteins such as Fc gamma receptors (FcγR) and neonatal Fc receptor (FcRn) is critical for gaining insight into canine immunology and for the discovery and development of therapeutic monoclonal antibodies for the treatment of canine malignancies.

Given the nascency of, but rapid growth and interest in, the canine immune-oncology field, there is a substantial need for biologically relevant methods to characterize binding properties of canine immunoglobulins.

The Lumit® Canine FcRn Immunoassay is a novel competition binding assay to aid researchers in evaluating canine IgG molecules. Lumit® assay technology is based on NanoBiT® luciferase complementation. LgBiT-labeled tracer binds to SmBiT-labeled cFcRn target, resulting in protein complementation and generation of bright luminescent signal. Addition of test antibodies that bind to cFcRn causes displacement of tracer, resulting in dose-dependent decrease in luminescence.

 

Discover an application for Lumit® Canine FcRn Assay in Morel, B. et al. (2024) Exploring the potentiality of a plant platform for monoclonal antibody production in veterinary medicine. Vaccines. 12, 620.

Read the paper
morelpaperscreenshot

Demonstrate Canine FcRn Binding Through Competition Immunoassay

19264ma

Principle of Lumit® Canine FcRn Immunoassay. Lumit® Canine FcRn (cFcRn) Binding Immunoassay is based on competition immunoassay format. In the assay, a human IgG1 labeled with LgBiT (Tracer-LgBiT) is used as the tracer. A C-terminal biotinylated canine FcRn bound to Streptavidin-SmBiT (cFcRn- SmBiT) is used as the target. In the absence of an antibody analyte sample, Tracer-LgBiT binds to the cFcRn-SmBiT target, resulting in maximum luminescence signal. In analyte samples, unlabeled IgG will compete with Tracer-LgBiT for binding to the FcRn target, resulting in a concentration-dependent decrease in luminescent signal.


Simple Assay Protocol: Add-Mix-Read

19265ma
  • Solution-Based Assay: No plate immobilization artifacts.
  • Homogeneous: Kit includes all of the required reagents in standardized formats.
  • Add-Mix-Read Protocol: No wash or transfer steps.

Lumit® Canine FcRn Assay Performance Data

Lumit® cFcRn Binding Immunoassay display window of raw signal at pH 6.0 (S/B ratio: ~70).
Lumit® cFcRn Binding Immunoassay display window of normalized signal at pH 6.0 (S/B ratio: ~70).

Lumit® cFcRn Binding Immunoassay displays a good assay window in both raw (Panel A) and normalized signal (Panel B) at pH 6.0 (S/B ratio: ~70).

Interested in additional animal health bioassays?

Contact us to learn about our bioassay development services.

Protocols

No protocols available

Specifications

Catalog Number:

What's in the box?

Item Part # Size

Canine FcRn-SmBiT

CS3019A03 1 × 40μl

Canine Tracer-LgBiT

CS3019A04 1 × 65μl

Control Canine Ab

CS3019A05 1 × 45μl

Lumit® Detection Substrate A

VB301D 1 × 75μl

FcRn Assay Buffer

W112A 1 × 25ml

pH Adjustment Buffer

W113A 1 × 250μl

Certificate of Analysis

Search by lot number

Storage Conditions

BB

Resources

Webinar: The Lumit® FcRn Binding Immunoassay as a Tool in the Development of Antibody-Based Therapeutics – Users Share Their Experiences

A prolonged plasma half-life of antibody-based drugs is desirable to boost therapeutic efficacy. Their concentration within the blood is in part governed by their affinity for the neonatal Fc receptor (FcRn). Characterizing and optimizing this interaction are therefore important steps in the development process. A widely applied method, surface plasmon resonance (SPR), is time-consuming and suffers from immobilization artifacts. With the Lumit® FcRn Binding Immunoassay, we have developed an effective, fast and solution-based SPR alternative.

Watch Webinar